UBS Group Has Lowered Expectations for Cabot (NYSE:CBT) Stock Price

Key Points

• UBS Group lowered Cabot’s price target from $92 to $86 while maintaining a “neutral” rating, implying 11.13% potential upside from the prior close.
• Analyst sentiment remains cautious: Cabot has a consensus “Hold” rating and an average target price of $87.80, based on two Buy, four Hold, and one Sell rating.
• Cabot shares rose 0.6% to $77.39, while the company’s latest quarterly results slightly exceeded expectations with $1.67 in EPS and $982 million in revenue; insiders have also sold approximately $19.6 million of stock over the past 90 days.

Cabot (NYSE:CBT - Get Free Report) had its price objective lowered by analysts at UBS Group from $92.00 to $86.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm presently has a "neutral" rating on the specialty chemicals company's stock. UBS Group's price target would indicate a potential upside of 11.13% from the stock's previous close.

A number of other research analysts also recently weighed in on CBT. Mizuho increased their target price on Cabot from $80.00 to $90.00 and gave the company a "neutral" rating in a report on Thursday, June 25th. Weiss Ratings reissued a "hold (c)" rating on shares of Cabot in a report on Friday, August 21st. JPMorgan Chase & Co. upped their target price on shares of Cabot from $70.00 to $78.00 and gave the company an "underweight" rating in a report on Friday, August 7th. Wall Street Zen downgraded shares of Cabot from a "buy" rating to a "hold" rating in a research report on Saturday. Finally, Truist Financial set a $100.00 target price on Cabot in a report on Wednesday, August 5th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Cabot presently has a consensus rating of "Hold" and a consensus target price of $87.80.

Cabot Stock Up 0.6%

Shares of NYSE:CBT traded up $0.44 during midday trading on Monday, reaching $77.39. The company's stock had a trading volume of 294,301 shares, compared to its average volume of 461,805. The company has a quick ratio of 0.97, a current ratio of 1.47 and a debt-to-equity ratio of 0.48. The firm has a 50 day moving average of $82.83 and a 200-day moving average of $82.22. Cabot has a 12-month low of $58.33 and a 12-month high of $94.53. The firm has a market capitalization of $3.99 billion, a P/E ratio of 21.80, a PEG ratio of 9.06 and a beta of 0.83.

Cabot (NYSE:CBT - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The specialty chemicals company reported $1.67 earnings per share for the quarter, beating analysts' consensus estimates of $1.66 by $0.01. The company had revenue of $982.00 million during the quarter, compared to analyst estimates of $943.16 million. Cabot had a return on equity of 20.29% and a net margin of 5.23%.The firm's revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter last year, the company earned $1.90 EPS. Cabot has set its FY 2026 guidance at 6.150-6.450 EPS. On average, research analysts anticipate that Cabot will post 6.35 earnings per share for the current year.

Insider Transactions at Cabot

In other Cabot news, CEO Sean Keohane sold 134,895 shares of the firm's stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $85.00, for a total transaction of $11,466,075.00. Following the sale, the chief executive officer directly owned 404,134 shares of the company's stock, valued at $34,351,390. This trade represents a 25.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 229,597 shares of company stock valued at $19,646,746. Corporate insiders own 3.08% of the company's stock.

Institutional Trading of Cabot

Several institutional investors and hedge funds have recently added to or reduced their stakes in CBT. BlackRock Inc. bought a new stake in shares of Cabot during the second quarter valued at approximately $633,302,000. State Street Corp increased its holdings in Cabot by 6.8% in the 2nd quarter. State Street Corp now owns 2,165,434 shares of the specialty chemicals company's stock valued at $196,665,000 after acquiring an additional 138,098 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Cabot by 4.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,742,782 shares of the specialty chemicals company's stock worth $131,253,000 after purchasing an additional 79,499 shares in the last quarter. Bank of America Corp DE bought a new position in shares of Cabot during the 2nd quarter valued at about $150,772,000. Finally, Sei Investments Co. grew its position in shares of Cabot by 6.5% during the first quarter. Sei Investments Co. now owns 1,051,578 shares of the specialty chemicals company's stock valued at $79,194,000 after purchasing an additional 64,122 shares in the last quarter. Institutional investors own 93.18% of the company's stock.

About Cabot

Cabot Corporation NYSE: CBT is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company develops and manufactures materials used by industrial and consumer-product manufacturers worldwide.

Cabot's products include reinforcing carbon blacks used in tires, automotive components, and other rubber products; specialty carbon blacks used in coatings, plastics, inks, and batteries; and fumed silica used in adhesives, sealants, coatings, and personal-care applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.